OABI Stock Analysis: OmniAb | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 670m USD | 12M Return: 202.5% | US68218J1034 | Charts, Fundamentals & Technical Analysis

Therapeutic Antibodies, Bispecific Antibodies, Single-Domain Antibodies, AI Discovery
Total Rating 55
Safety 61
Buy Signal 0.68
Biotechnology
Industry Rotation: -16.6
Market Cap: 670M
Avg Turnover: 5.78M
Risk 3d forecast
Volatility60.5%
VaR 5th Pctl9.61%
VaR vs Median-3.52%
Reward TTM
Sharpe Ratio1.77
Rel. Str. IBD99.3
Rel. Str. Peer Group95.3
Character TTM
Beta0.807
Beta Downside1.481
Hurst Exponent0.690
Drawdowns 3y
Max DD81.32%
CAGR/Max DD-0.02
CAGR/Mean DD-0.03
EPS (Earnings per Share) EPS (Earnings per Share) of OABI over the last years for every Quarter: "2021-09": -0.01, "2021-12": -0.01, "2022-03": -0.16, "2022-06": -0.06, "2022-09": -0.09, "2022-12": 0.07, "2023-03": -0.06, "2023-06": -0.15, "2023-09": -0.16, "2023-12": -0.14, "2024-03": -0.19, "2024-06": -0.13, "2024-09": -0.16, "2024-12": -0.12, "2025-03": -0.17, "2025-06": -0.15, "2025-09": -0.14, "2025-12": -0.11, "2026-03": -0.06, "2026-06": -0.05,
Last SUE: 2.33
Qual. Beats: 2
Revenue Revenue of OABI over the last years for every Quarter: 2021-09: 6.277, 2021-12: 15.28, 2022-03: 9.623, 2022-06: 7.199, 2022-09: 6.91, 2022-12: 35.345, 2023-03: 16.919, 2023-06: 6.946, 2023-09: 5.477, 2023-12: 4.822, 2024-03: 3.801, 2024-06: 7.614, 2024-09: 4.172, 2024-12: 10.804, 2025-03: 4.154, 2025-06: 3.897, 2025-09: 2.239, 2025-12: 8.375999, 2026-03: 14.4, 2026-06: 13.415,
Rev. CAGR: -10.38%
Rev. Trend: -28.1%
Last SUE: 2.17
Qual. Beats: 2

Warnings

Strong Share Dilution

Tailwinds

Rs Leader
Idiosyncratic Leader

Seasonality 4.9 years of data

Jan -2.1% 21
Feb +1.2% 20
Mar -9.3% 51
Apr -13.2% 48
May +11.6% 21
Jun +4.0% 0
Jul +13.1% 23
Aug -1.2% 0
Sep +3.0% 22
Oct -6.9% 0
Nov -2.6% 19
Dec +2.6% 21

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: OABI OmniAb

OmniAb, Inc. (NASDAQ: OABI) is a biotechnology company that licenses its antibody discovery research platform to pharmaceutical and biotech firms as well as academic institutions across the United States, Europe, Japan, China, and Canada. The companys business model centers on a royalty and licensing structure, generating revenue by providing partners access to its proprietary transgenic animal technologies and AI-driven discovery tools rather than developing its own commercial drug pipeline.

The companys core offering is its OmniAb platform, which uses Biological Intelligence to harness the immune systems of genetically modified animals-including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmniTaur, and OmnidAb-to generate optimized antibody candidates for human therapeutics. The platform is complemented by OmniDeep, a suite of AI and machine learning tools for therapeutic discovery and optimization. OmniAb has also entered an agreement with mAbsolve Ltd. to integrate Fc-silencing STR technology into antibodies generated through its discovery platform. Founded in 2012 and headquartered in Emeryville, California, OmniAb operates within the biotechnology sub-industry and completed its IPO in late 2022.

Headlines to Watch Out For
  • New antibody platform licensing deals expand partner base
  • Partner clinical milestones trigger milestone and royalty payments
  • AI-powered OmniDeep adoption accelerates versus competing discovery platforms
Piotroski VR-10 (Strict) 1.5
Net Income: -44.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA 4.59 > 1.0
NWC/Revenue: 136.0% < 20% (prev 151.9%; Δ -15.93% < -1%)
CFO/TA -0.06 > 3% & CFO -17.7m > Net Income -44.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.80 > 1.5 & < 3
Outstanding Shares: last quarter (128.8m) vs 12m ago 21.34% < -2%
Gross Margin: 50.53% > 18% (prev 14.52%; Δ 36.01% > 0.5%)
Asset Turnover: 13.12% > 50% (prev 7.79%; Δ 5.33% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 7.17
A: 0.18 (Total Current Assets 66.0m - Total Current Liabilities 13.8m) / Total Assets 290.3m
B: -0.62 (Retained Earnings -179.7m / Total Assets 290.3m)
C: -0.17 (EBIT TTM -48.3m / Avg Total Assets 293.0m)
D: 8.68 (Book Value of Equity 260.3m / Total Liabilities 30.0m)
Altman-Z'' = 7.17 = AAA
Beneish M -2.18
DSRI: 2.29 (Receivables 10.3m/2.71m, Revenue 38.4m/23.0m)
GMI: 0.29 (GM 14.52% / 50.53%)
AQI: 0.94 (AQ_t 0.69 / AQ_t-1 0.73)
SGI: 1.67 (Revenue 38.4m / 23.0m)
TATA: -0.09 (NI -44.3m - CFO -17.7m) / TA 290.3m)
Beneish M = -2.18 (Cap -4..+1) = BB
What is the price of OABI shares?

As of October 06, 2026, the stock is trading at USD 4.87 with a total of 1,623,646 shares traded. Over the past week, the price has changed by +5.64%, over one month by -3.37%, over three months by +101.24% and over the past year by +202.48%.

Current recommended Stop Loss: 4.10 (which is 15.8% or 2.7 ATR below the current price).

Is OABI a buy, sell or hold?

OmniAb has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy OABI.

  • StrongBuy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the OABI price?
Analysts Target Price 8.4 72.5%
OmniAb (OABI) - Fundamental Data Overview as of 04 October 2026
Market Cap USD = 670.2m (670.2m USD * 1.0 USD.USD)
P/S = 17.4286
P/B = 2.6757
Revenue TTM = 38.4m USD
EBIT TTM = -48.3m USD
EBITDA TTM = -24.5m USD
Long Term Debt = 14.9m USD (estimated: total debt 18.9m - short term 3.97m)
Short Term Debt = 3.97m USD (from shortTermDebt, last quarter)
Debt = 18.9m USD (from shortLongTermDebtTotal, last quarter) (leases 18.9m already included)
Net Debt = -33.1m USD (calculated: Debt 18.9m - CCE 52.0m)
Enterprise Value = 637.2m USD (670.2m + Debt 18.9m - CCE 52.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -48.3m / Interest Expense TTM 0.0)
 EV/FCF = -35.13x (Enterprise Value 637.2m / FCF TTM -18.1m)
FCF Yield = -2.85% (FCF TTM -18.1m / Enterprise Value 637.2m)
FCF Margin = -47.20% (FCF TTM -18.1m / Revenue TTM 38.4m)
Net Margin = -115.2% (Net Income TTM -44.3m / Revenue TTM 38.4m)
Gross Margin = 50.53% ((Revenue TTM 38.4m - Cost of Revenue TTM 19.0m) / Revenue TTM)
Gross Margin QoQ = none% (prev 58.33%)
Tobins Q-Ratio = 2.20 (Enterprise Value 637.2m / Total Assets 290.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 18.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -38.2m (EBIT -48.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.80 (Total Current Assets 66.0m / Total Current Liabilities 13.8m)
Debt / Equity = 0.07 (Debt 18.9m / totalStockholderEquity, last quarter 260.3m)
 Debt / EBITDA = 1.35 (negative EBITDA) (Net Debt -33.1m / EBITDA -24.5m)
 Debt / FCF = 1.82 (negative FCF - burning cash) (Net Debt -33.1m / FCF TTM -18.1m)
 Total Stockholder Equity = 266.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.11% (Net Income -44.3m / Total Assets 290.3m)
RoE = -16.59% (Net Income TTM -44.3m / Total Stockholder Equity 266.8m)
RoCE = -17.16% (EBIT -48.3m / Capital Employed (Equity 266.8m + L.T.Debt 14.9m))
 RoIC = -13.71% (negative operating profit) (NOPAT -38.2m / Invested Capital 278.6m)
 WACC = 8.58% (E(670.2m)/V(689.2m) * Re(8.82%) + D(18.9m)/V(689.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.62 | Cagr: 11.53%
 [DCF] Fair Price = unknown (Cash Flow -18.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.33 | # QB: 2
Revenue Correlation: -28.12 | Revenue CAGR: -10.38% | SUE: 2.17 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.13 | Chg30d=-10.64% | Revisions=-29% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.37 | Chg30d=+12.02% | Revisions=+62% | GrowthEPS=+35.8% | GrowthRev=+87.3%
EPS next Year (2027-12-31): EPS=-0.29 | Chg30d=+8.53% | Revisions=+57% | GrowthEPS=+19.4% | GrowthRev=+24.4%
[Analyst] Revisions Ratio: +44% (up=10, down=3)